FDA Approves Azacitidine for AML Continued Treatment

On September 1, 2020 the U.S. Food and Drug Administration (FDA) approved Onureg® (azacitidine) for the continued treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Read the Bristol Myers Squibb announcement.

Read the FDA announcement.

Posted 9/2/2020